NC-LENOVO/FORMULA-1
10.3.2022 14:32:13 CET | Business Wire | Press release
Formula 1 and Lenovo announced today that Lenovo is an Official Partner ahead of the upcoming 2022 season. The multi-year deal will see Lenovo’s cutting-edge technology used across Formula 1’s operations as it continues to bring the highest-level of racing and entertainment to its worldwide fanbase. As global leaders in their respective fields, Formula 1 and Lenovo want to push the boundaries of what’s possible when combining sports with advanced technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005287/en/
Over the next few years, the partnership will involve Lenovo’s technology being used across the Formula 1 organization, both back at its base and at races. Lenovo’s hardware devices, as well as High Performance Computing and server solutions will be increasingly integrated throughout the organisation’s operations. From running powerful on-premises data collection solutions to producing higher quality content and supporting broadcast applications, the Formula 1 and Lenovo collaboration will result in a better experience for fans.
The partnership will drive global visibility of Lenovo, showcasing Lenovo’s capabilities on a global scale and integrating industry-leading hardware technology at the heart of Formula 1. It plans to leverage Lenovo’s extensive selection of premium hardware as well as innovative next-generation technology such as augmented and virtual reality, as F1 continues to connect fans with the sport in new and more engaging ways.
Earlier this year, F1 announced that it has extended its commitment to create employment and education opportunities for underrepresented groups, in the form of ten engineering scholarships each year through to 2025. Lenovo is also focused on diversity and inclusion and removing barriers, and through the partnership will work with F1 on projects related to this important area.
Stefano Domenicali, President & CEO of Formula 1, said:
“As we prepare for our record-breaking season, it is exciting to welcome Lenovo to the team and for us to join forces with a global leader in technology. Like everything in Formula 1, precision and detail are everything, and Lenovo will be at the forefront of providing their experience and innovative technologies to our operations throughout the season. Our fans expect the best from everything we do, and Lenovo is the perfect partner in terms of its premium hardware offerings. We are entering a new era of our sport and we’re committed to delivering a high-quality experience for our dedicated followers around the world.”
Yang Yuanqing, Chairman & CEO of Lenovo, said:
“We are proud to announce our new global partnership with Formula 1, the world’s most prestigious motor racing competition, to engage half a billion fans all over the world with exciting, innovative experiences. This partnership is based on our shared passion for innovation, performance, and the winning spirit. Together Lenovo and Formula 1 will push the limits of technology to help shape a faster, smarter, and more sustainable future.”
Luca Rossi, President of Intelligent Devices Group, Lenovo, said:
“Partnering with Formula 1 to deploy Lenovo’s smarter solutions across the organization, from base operations to the stunning excitement of the Grands Prix, will help push the boundaries of what is possible and transform the racing experience. Formula 1 is focused on its digital transformation and continuing to surprise and delight its fans. Lenovo’s portfolio of hardware, services and solutions will be key to helping Formula 1 create new ways for fans around the world to experience the same thrills you’d experience track side.”
About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com , and read about the latest news via our StoryHub .
LENOVO is a trademark of Lenovo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom